An observational study in Myeloma, sponsored by The Royal Wolverhampton Hospitals NHS Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by The Royal Wolverhampton Hospitals NHS Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom — 5 open to participants now, 6 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United Kingdom.
Among the 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 38th registered.
710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.
Browse Neoplasms, Plasma Cell studies →5 of the 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+
Pfizer · Sites in United Kingdom, United States, Argentina and 24 more countries
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18+
The Christie NHS Foundation Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 15
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 150 across 83 observational studies indexed under Neoplasms, Plasma Cell.
Median enrollment 114 across the 33 interventional studies, 64 across the 6 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 39 have an industry lead sponsor. The 10 most frequent:
The Royal Wolverhampton Hospitals NHS Trust is the lead sponsor of 51 studies on the registry; 15 are open to participants now.
The Royal Wolverhampton Hospitals NHS Trust has 1 study filed under Neoplasms, Plasma Cell — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) for transplant ineligible (TIE) untreated myeloma patients (MAIA) was reported in 2019. NICE approved this in September 2023 and since this time DRd has become the standard of care regimen for TIE patients with newly diagnosed multiple myeloma in the UK. Although there are reports of real world experience (RWE) of DRd efficacy in relapsed setting, there are no RWE reports of DRd efficacy and outcomes from the UK where it is used in the upfront setting and very limited data from Europe. Moreover, UK clinicians often adopt a pragmatic dose adjustment approach, particularly in the dosing of lenalidomide (escalation and de-escalation) with steroid tapering. As well as reducing short-term toxicities, this approach may lead to longer term benefits by reducing long-term steroid adverse effects such as steroid-induced diabetes, help ameliorate immune paresis and reduce infection risk.
However, there is very limited data on the efficacy and outcomes of this practice. In particular, there is no published RWE on the impact of pre-emptive dose modifications on tolerability and efficacy in frail patients, the cohort in which the highest treatment discontinuation rates were observed in the MAIA trial. It is also perceived that patients with comorbidities, which would have been excluded in MAIA cohort, are benefiting from this flexible approach in real world practice, especially people with chronic kidney disease and other comorbidities. A proportion of patients initially deemed fit for autologous stem cell transplantation (received D-VTD as induction) are also receiving DRd if they fail to receive a transplant. These patients were not represented in the MAIA study and the outcomes following de-escalation from D-VTD to DRd are unknown.
Sites participating in this study will be those who have prescribed DRd for newly diagnosed transplant ineligible patients since this triple combination was reimbursed for use in the UK healthcare system in 2023.
Within the study, data will be collected from the medical records of adult patients aged ≥18 years with ND MM, who are ineligible for transplant and who have received at least one dose of DRd outside of clinical trials.
To be eligible for inclusion in the study, the date of the first dose should be:
Data will be analysed in Q1 2026 to assess treatment outcomes at 12 months (to 31 December 2025) and in Q1 2027 to assessment 12- and 24-months treatment outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall response rate (OOR) at 12 months
Proportion with partial response (PR) or better (per IMWG criteria).
Time frame: 12 months
Real-world dosing strategy for DRd - starting doses of Daratumumab, Lenalidomide and dexamethasone in cycle 1 and relative dose intensity at 12 months
% of patients who have had a dose adjustment in any of the DRD treatment components within the first 12 months of treatment
Time frame: 12 months
Progression -Free Survival (PFS) at 12 and 24 months
Time from first dose to documented disease progression or death (whichever first) Median time to disease progression or death
Time frame: 12 months and 24 months
Overall survival at 12 and 24 months
Time from first dose to death from any cause
Time frame: 12 months and 24 months
Very good partial response (VGPR)
Per IMWG response definitions (CR = negative immunofixation in serum \& urine + \<5% bone-marrow plasma cells; sCR adds normal free light-chain ratio and absence of clonal plasma cells).
Time frame: 24 months
Occurrence of severe infections
% of patients who have had a grade 3 or 4 infection within 12 or 24 months of starting treatment
Time frame: 12 months and 24 months from starting treatment
Treatment exposure /discontinuation (Treatment deliverability)
Median duration of treatment % treatment discontinuation before 12 and 24 months
Time frame: 12 months and 24 months
Dosing practice and outcome difference between academic and DGH trusts
Time frame: 12 months and 24 months
Treatment setting
Proportion of patients receiving daratumumab in the community via an outreach service
Time frame: 12 months and 24 months
Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Royal Wolverhampton Hospitals NHS Trust